Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based
molecular diagnostics, today announced that Tom McLain, Chief Executive
Officer of Exosome Diagnostics, will present today at the fourth annual OktoberINVESTfest
at the New York Academy of Sciences in New York City.
Mr. McLain’s presentation will focus on the evolving role of diagnostics
in advancing personalized medicine and the progress that Exosome
Diagnostics has made in this field. Exosome Diagnostics plans to launch
in 2015 a suite of innovative liquid biopsy tests based on its
proprietary, exosome-based ExoLution™ platform to enhance mutation
detection, screening, and drug-resistance monitoring for various types
of cancer.
Exosomes are messengers released by all living cells into biofluids,
such as plasma/serum, urine, cerebrospinal fluid and saliva. They
contain RNA, DNA and proteins from their cell of origin. Exosome
Diagnostics’ technology platform can achieve real-time access to
comprehensive molecular information about cells in the body without
direct access to the actual cells.
The company is also exploring the development of exosome-based
diagnostics for diseases beyond cancer, including neurodegenerative
diseases.
Exosome Diagnostics’ global headquarters and CLIA-certified laboratory
are located in Cambridge, Mass., and the company’s European headquarters
and research laboratory are located in the Innovation and Startup Center
for Biotechnology IZB in Martinsried, Germany.
About Exosome Diagnostics
Exosome Diagnostics is a privately held company focused on developing
and commercializing revolutionary biofluid-based diagnostics to deliver
personalized precision healthcare that improves lives. The company’s
novel exosome-based technology platform, ExoLution™, can yield
comprehensive and dynamic molecular insights to transform how cancer and
other serious diseases are detected, diagnosed, treated and monitored.
Visit www.exosomedx.com
to learn more.
Exosome Diagnostics and ExoLution are registered and unregistered
trademarks of Exosome Diagnostics, Inc.
About Invest in Bavaria
Invest in Bavaria was established in 1999 to serve as the investment
promotion agency for the German State of Bavaria by supporting companies
from around the world to find ideal locations to set up businesses
and/or identify investment opportunities in the state. The organization
has played a vital role in connecting US investors and business leaders
with Bavaria’s strategic and competitive advantages, in addition to
providing them with cost-free, confidential professional services to
assist in their investment and site selection process. Additionally, the
organization assists Bavarian companies considering international
expansion. The Bavarian US offices for Economic Development, LLC, is the
representative organization for Invest in Bavaria in the US. There are
26 representative offices of Invest in Bavaria globally, including
offices in New York, New Haven and San Francisco. For additional
information, please visit http://www.invest-in-bavaria.com/.
View source version on businesswire.com:
http://www.businesswire.com/news/home/20151013005122/en/
Business Wire
http://www.businesswire.com/
Last updated on: 13/10/2015